PRCT

BEARISH

$25.14 Live

PROCEPT BioRobotics Corporation · NASDAQ

Target $30.11 (+19.8%)

$19.35 52W Range $66.85

PRCT PROCEPT BioRobotics Corporation - Fundamental Analysis

BEARISH

Console Chart News

PRCT Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Medical Devices

Current Price Live

$25.14

Analyst Target

$30.11

+19.8% Upside

52W High

$66.85

52W Low

$19.35

Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026

Market cap

$1.42B

P/E

N/A

ROE

-24.9%

Profit margin

-31.0%

Debt/Equity

0.21

Dividend yield

N/A

AI Analysis

AI-powered fundamental assessment

Confidence

85%

PRCT presents a dichotomy between a strong balance sheet and a deteriorating operational and market profile. While the Piotroski F-Score of 5/9 indicates stable financial health and the current ratio of 6.84 shows exceptional liquidity, these are overshadowed by a -52.6% one-year price collapse and negative profit margins. The company is struggling with earnings growth (-51.4% YoY) and exhibits a strong bearish technical trend. Despite analyst 'buy' recommendations, the combination of insider selling and negative EPS progression suggests significant headwinds.

Key Strengths

Strong Gross Margin (63.70%) indicating a viable core product

Exceptional liquidity with a Current Ratio of 6.84

Very low leverage with a Debt/Equity ratio of 0.21

Consistent positive revenue growth (11.9% YoY)

Strong analyst support with a target price of $30.11

Key Risks

Severe technical downtrend (1Y Change: -52.6%)

Negative profitability with an operating margin of -40.64%

Declining earnings performance (YoY EPS Growth: -51.4%)

Bearish insider sentiment with consistent selling and zero buying

High valuation relative to earnings (Forward P/E is negative)

AI Fair Value Estimate

Based on comprehensive analysis

$27.5

+9.4% above current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall

Weak

Value

Future

Past

Health

Dividend

AI Verdict

Speculative/High Risk

Key drivers: Strong balance sheet liquidity, Severe price depreciation, Negative earnings trajectory, Insider divestment

Confidence

90%

Value

30/100

Ref P/E, PEG, Graham Number

Positives

P/S ratio of 4.60 is moderate for medical devices

Watchpoints

No Graham Number due to lack of earnings
Negative Forward P/E
P/B of 3.87 is elevated for a non-profitable firm

Future

45/100

Ref Growth rates

Positives

Steady revenue growth of ~12%

Watchpoints

EPS growth is crashing (-51.4% YoY)
Recent earnings surprises are trending negative

Past

20/100

Ref Historical trends

Positives

Historical ability to beat some estimates

Watchpoints

Catastrophic 1Y price performance (-52.6%)
Negative 3Y and 5Y returns

Health

75/100

Ref Altman Z-Score, Piotroski F-Score

Positives

Piotroski F-Score of 5/9 (Stable)
Very low Debt/Equity (0.21)
High Quick Ratio (5.62)

Watchpoints

Negative ROE and ROA

Dividend

0/100

Ref Yield, Payout

Positives

No standout positives identified.

Watchpoints

No dividend paid
0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price

$25.14

Analyst Target

$30.11

Upside/Downside

+19.8%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PRCT and closest competitors.

Updated 2026-04-17

Company	5Y	3Y	1Y	6M	1M	1W
PRCT PROCEPT BioRobotics Corporation Primary	-40.1%	-32.1%	-52.6%	-23.8%	-3.9%	+8.4%
ARDX Ardelyx, Inc. Peer	-17.1%	+46.3%	+6.6%	-12.6%	-20.4%	-6.6%
NVAX Novavax, Inc. Peer	-96.2%	-8.1%	+36.0%	-2.5%	-13.8%	+3.2%
BCRX BioCryst Pharmaceuticals, Inc. Peer	-25.9%	-38.3%	-12.2%	-20.6%	-11.8%	+1.9%
IMTX Immatics N.V. Peer	-10.0%	+69.3%	+162.7%	+0.7%	+4.0%	+0.8%

PRC

PROCEPT BioRobotics Corporation

Primary

-40.1%

-32.1%

-52.6%

-23.8%

-3.9%

+8.4%

ARD

Ardelyx, Inc.

Peer

-17.1%

+46.3%

+6.6%

-12.6%

-20.4%

-6.6%

NVA

Novavax, Inc.

Peer

-96.2%

-8.1%

+36.0%

-2.5%

-13.8%

+3.2%

BCR

BioCryst Pharmaceuticals, Inc.

Peer

-25.9%

-38.3%

-12.2%

-20.6%

-11.8%

+1.9%

IMT

Immatics N.V.

Peer

-10.0%

+69.3%

+162.7%

+0.7%

+4.0%

+0.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

N/A

-28.47

N/A

3.87

4.6

3.93

-12.41

$1.42B

Profitability

Profit margins and return metrics

Profit Margin -31.02%

Operating Margin -40.64%

Gross Margin 63.7%

ROE -24.89%

ROA -12.46%

Growth

Revenue and earnings growth rates

Revenue Growth +11.9%

Earnings Growth N/A

Q/Q Revenue Growth +11.94%

Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity

0.21

Low debt

Current Ratio

6.84

Strong

Quick Ratio

5.62

Excellent

Cash/Share

$5.08

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue

$0.1B

Gross Margin

60.6%

Op. Margin

-40.6%

Net Margin

-39.1%

Total Assets

$0.5B

Liabilities

$0.1B

Equity

$0.4B

Debt/Equity

0.39x

Operating CF

$-0.0B

CapEx

$-0.0B

Free Cash Flow

$-0.0B

FCF Yield

118%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-29

$N/A

2026-02-25

$-0.53

-61.6% surprise

2025-11-04

$-0.38

+9.8% surprise

2025-08-06

$-0.35

+14.6% surprise

Healthcare Sector Comparison

Comparing PRCT against 418 companies in the Healthcare sector (24 bullish, 134 neutral, 260 bearish)

Return on Equity (ROE)

-24.89%

This Stock

-101.05%

Sector Avg

-75.4% (Below Avg)

Profit Margin

-31.02%

This Stock

-13.75%

Sector Avg

+125.6% (Superior)

Debt to Equity

0.21

This Stock

3.24

Sector Avg

-93.4% (Less Debt)

Revenue Growth

11.9%

This Stock

121.5%

Sector Avg

-90.2% (Slower)

Current Ratio

6.84

This Stock

4.55

Sector Avg

+50.3% (Stronger)

Similar Companies

Peer comparison within the same industry

Company	AI Rating	Market Cap	P/E	ROE	Profit Margin	Price
PRCT PROCEPT BioRobotics Corporation	BEARISH	$1.42B	-	-24.9%	-31.0%	$25.14
ARDX Ardelyx, Inc.	NEUTRAL	$1.42B	-	-36.2%	-15.1%	$5.78	Compare
NVAX Novavax, Inc.	NEUTRAL	$1.42B	3.25	-%	39.2%	$8.69	Compare
BCRX BioCryst Pharmaceuticals, Inc.	NEUTRAL	$1.43B	-	-%	-1.5%	$6.79	Compare
IMTX Immatics N.V.	BEARISH	$1.4B	-	-37.1%	-%	$10.43	Compare

PRCT PROCEPT...

BEARISH

Mkt Cap

$1.4B

P/E

ROE

-24.9%

Price

$25.14

Compare with PRCT

Compare with PRCT

Compare with PRCT

Compare with PRCT

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

Date	Insider	Position	Transaction	Shares	Value
2026-03-19	NOURI ALALEH	Officer	Sale	5,363	$139,231
2026-03-17	NOURI ALALEH	Officer	Sale	304	$8,559
2026-03-17	WATERS KEVIN	Chief Financial Officer	Sale	706	$19,876
2026-03-10	NOURI ALALEH	Officer	Sale	3,243	$83,197
2026-03-09	DESAI ANTAL ROHIT	Director	Purchase	426,262	$10,482,943
2026-03-06	NOURI ALALEH	Officer	Sale	6,892	$163,353
2026-03-06	WATERS KEVIN	Chief Financial Officer	Sale	6,721	$159,300
2026-03-05	NOURI ALALEH	Officer	Stock Award	43,811	-
2026-03-05	WATERS KEVIN	Chief Financial Officer	Stock Award	47,462	-
2026-03-05	PUCKETT DANIEL	Director	Stock Award	5,476	-
2026-03-05	WOOD LARRY L	Chief Executive Officer	Stock Award	127,783	-
2026-02-19	NOURI ALALEH	Officer	Stock Award	4,872	-
2026-02-19	WATERS KEVIN	Chief Financial Officer	Stock Award	3,532	-

NOURI ALALEH

Officer

Sell

2026-03-19

5,363 shares · $139,231

NOURI ALALEH

Officer

Sell

2026-03-17

304 shares · $8,559

WATERS KEVIN

Chief Financial Officer

Sell

2026-03-17

706 shares · $19,876

NOURI ALALEH

Officer

Sell

2026-03-10

3,243 shares · $83,197

DESAI ANTAL ROHIT

Director

Buy

2026-03-09

426,262 shares · $10,482,943

NOURI ALALEH

Officer

Sell

2026-03-06

6,892 shares · $163,353

WATERS KEVIN

Chief Financial Officer

Sell

2026-03-06

6,721 shares · $159,300

NOURI ALALEH

Officer

Stock Award

2026-03-05

43,811 shares

WATERS KEVIN

Chief Financial Officer

Stock Award

2026-03-05

47,462 shares

PUCKETT DANIEL

Director

Stock Award

2026-03-05

5,476 shares

WOOD LARRY L

Chief Executive Officer

Stock Award

2026-03-05

127,783 shares

NOURI ALALEH

Officer

Stock Award

2026-02-19

4,872 shares

WATERS KEVIN

Chief Financial Officer

Stock Award

2026-02-19

3,532 shares

Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K

2026-03-06

10-K

2026-02-26

PRCT filed its annual 10-K report on February 26, 2026. Due to the absence of detailed text in the provided excerpts, specific financial highlights and risk factors cannot be determined.

8-K

2026-02-26

Precigen, Inc. filed an 8-K likely reporting its fourth-quarter and full-year financial results for the fiscal year ended December 31, 2025.

8-K

2026-02-25

Precigen, Inc. filed an 8-K on February 25, 2026, likely to report its annual financial results or a material corporate update.

10-Q

2025-11-05

PRCT filed its quarterly 10-Q report on November 5, 2025. The filing includes a section on Risk Factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K

2025-11-04

8-K

2025-09-18

10-Q

2025-08-07

PRCT filed its quarterly 10-Q report on August 7, 2025. The filing includes a section on Risk Factors under Item 1A, although specific financial highlights and detailed risk descriptions were not provided in the available excerpt.

8-K

2025-08-06

Precigen, Inc. filed an 8-K likely reporting its second-quarter financial results for 2025.

8-K

2025-07-25

Precigen, Inc. filed an 8-K likely announcing its second quarter 2025 financial results.

8-K

2025-06-11

10-Q

2025-05-02

DEF 14A

2025-04-25

8-K

2025-04-25

8-K

2025-04-24

Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus

BUY

9 analysts

Baird

2026-03-06

init

Neutral

Truist Securities

2026-03-02

Maintains

Buy Buy

Leerink Partners

2026-02-26

Maintains

Outperform Outperform

TD Cowen

2026-02-26

Maintains

Buy Buy

Oppenheimer

2026-02-26

down

Outperform Perform

Piper Sandler

2026-02-26

Maintains

Overweight Overweight

Wells Fargo

2026-02-26

Maintains

Overweight Overweight

B of A Securities

2026-02-26

down

Neutral Underperform

Truist Securities

2025-12-18

Maintains

Buy Buy

UBS

2025-12-12

init

Buy

Past News Coverage

Recent headlines mentioning PRCT from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V2 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends

PRCT

PRCT PROCEPT BioRobotics Corporation - Fundamental Analysis

At a glance

AI Analysis

Key Strengths

Key Risks

Performance Snowflake

Stock Price & Analyst Targets

Multi-Horizon Performance vs Peers

Historical Performance Trends

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Valuation Metrics

Profitability

Growth

Financial Health

Financial Statement Flow

Quarterly Earnings History

Healthcare Sector Comparison

Similar Companies

Recent Insider Trading

SEC Filings

Wall Street Analysts

Past News Coverage

Wait — Don't Miss Out!